QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   905.86 (+0.37%)
NIO   4.55 (-2.57%)
AMD   180.65 (+0.59%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.19 (+1.00%)
MU   117.66 (-1.24%)
CGC   9.64 (+0.94%)
GE   174.80 (-2.95%)
DIS   122.61 (+1.35%)
AMC   3.69 (-14.98%)
PFE   28.01 (+0.83%)
PYPL   67.21 (+0.96%)
XOM   115.91 (+0.82%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   905.86 (+0.37%)
NIO   4.55 (-2.57%)
AMD   180.65 (+0.59%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.19 (+1.00%)
MU   117.66 (-1.24%)
CGC   9.64 (+0.94%)
GE   174.80 (-2.95%)
DIS   122.61 (+1.35%)
AMC   3.69 (-14.98%)
PFE   28.01 (+0.83%)
PYPL   67.21 (+0.96%)
XOM   115.91 (+0.82%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   905.86 (+0.37%)
NIO   4.55 (-2.57%)
AMD   180.65 (+0.59%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.19 (+1.00%)
MU   117.66 (-1.24%)
CGC   9.64 (+0.94%)
GE   174.80 (-2.95%)
DIS   122.61 (+1.35%)
AMC   3.69 (-14.98%)
PFE   28.01 (+0.83%)
PYPL   67.21 (+0.96%)
XOM   115.91 (+0.82%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   905.86 (+0.37%)
NIO   4.55 (-2.57%)
AMD   180.65 (+0.59%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.19 (+1.00%)
MU   117.66 (-1.24%)
CGC   9.64 (+0.94%)
GE   174.80 (-2.95%)
DIS   122.61 (+1.35%)
AMC   3.69 (-14.98%)
PFE   28.01 (+0.83%)
PYPL   67.21 (+0.96%)
XOM   115.91 (+0.82%)

Xeris Biopharma (XERS) Stock Price, News & Analysis

$2.20
+0.16 (+7.84%)
(As of 01:16 PM ET)
Today's Range
$2.11
$2.28
50-Day Range
$2.04
$3.22
52-Week Range
$1.31
$3.26
Volume
2.21 million shs
Average Volume
2.36 million shs
Market Capitalization
$308.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.83

Xeris Biopharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
118.6% Upside
$4.88 Price Target
Short Interest
Bearish
6.58% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.57
Upright™ Environmental Score
News Sentiment
1.87mentions of Xeris Biopharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$9,720 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.37) to ($0.16) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.53 out of 5 stars

Medical Sector

113th out of 939 stocks

Biotechnology Industry

4th out of 24 stocks

XERS stock logo

About Xeris Biopharma Stock (NASDAQ:XERS)

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

XERS Stock Price History

XERS Stock News Headlines

Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Q4 2023 Xeris Biopharma Holdings Inc Earnings Call
Xeris Biopharma Shares Drop After Weak 4Q Results
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
3 Breakout Stocks Under $5 to Buy for More Upside
Big Game or Small, Here's How to Go About Stalking a Trade
Xeris Biopharma Updates Its Outlook for 2023
See More Headlines
Receive XERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:XERS
Fax
N/A
Employees
377
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.88
High Stock Price Target
$6.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+117.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-62,260,000.00
Pretax Margin
-38.74%

Debt

Sales & Book Value

Annual Sales
$163.91 million
Book Value
($0.05) per share

Miscellaneous

Free Float
134,329,000
Market Cap
$311.80 million
Optionable
Optionable
Beta
2.37

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Paul R. EdickMr. Paul R. Edick (Age 68)
    Chairman & CEO
    Comp: $1.12M
  • Mr. John P. Shannon (Age 62)
    President & COO
    Comp: $827.72k
  • Ms. Beth P. Hecht J.D. (Age 60)
    Chief Legal Officer & Corporate Secretary
    Comp: $638.31k
  • Mr. Steven M. Pieper (Age 47)
    Chief Financial Officer
  • Ms. Allison Wey
    Senior Vice President of Investor Relations & Corporate Communications
  • Dr. Kenneth E. Johnson Pharm. D. (Age 61)
    Pharm.D., Senior VP of Global Development & Medical Affairs
  • Mr. Kevin McCulloch
    Chief Commercial Officer

XERS Stock Analysis - Frequently Asked Questions

Should I buy or sell Xeris Biopharma stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xeris Biopharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XERS shares.
View XERS analyst ratings
or view top-rated stocks.

What is Xeris Biopharma's stock price target for 2024?

4 Wall Street analysts have issued 12 month target prices for Xeris Biopharma's shares. Their XERS share price targets range from $4.00 to $6.00. On average, they anticipate the company's share price to reach $4.88 in the next year. This suggests a possible upside of 118.6% from the stock's current price.
View analysts price targets for XERS
or view top-rated stocks among Wall Street analysts.

How have XERS shares performed in 2024?

Xeris Biopharma's stock was trading at $2.35 on January 1st, 2024. Since then, XERS stock has decreased by 5.1% and is now trading at $2.23.
View the best growth stocks for 2024 here
.

When is Xeris Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our XERS earnings forecast
.

How were Xeris Biopharma's earnings last quarter?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) announced its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. The company earned $44.39 million during the quarter, compared to analyst estimates of $45.50 million. Xeris Biopharma had a negative trailing twelve-month return on equity of 610.76% and a negative net margin of 37.98%. During the same quarter in the prior year, the company earned ($0.10) earnings per share.

What ETF holds Xeris Biopharma's stock?

iShares Neuroscience and Healthcare ETF holds 15,969 shares of XERS stock, representing 0.79% of its portfolio.

What guidance has Xeris Biopharma issued on next quarter's earnings?

Xeris Biopharma updated its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $170.0 million-$200.0 million, compared to the consensus revenue estimate of $188.0 million.

What other stocks do shareholders of Xeris Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Biopharma investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Miragen Therapeutics (MGEN), Novan (NOVN), Dynavax Technologies (DVAX), Zosano Pharma (ZSAN), Cogent Biosciences (UMRX) and Organigram (OGI).

When did Xeris Biopharma IPO?

Xeris Biopharma (XERS) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Mizuho Securities was co-manager.

Who are Xeris Biopharma's major shareholders?

Xeris Biopharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.13%), Vanguard Group Inc. (5.05%), Stonepine Capital Management LLC (4.30%), Northern Trust Corp (0.84%), Invenomic Capital Management LP (0.41%) and Nuveen Asset Management LLC (0.31%). Insiders that own company stock include Jeffrey W Sherman, John P Schmid, John Patrick Shannon Jr, Paul R Edick and Steven Prestrelski.
View institutional ownership trends
.

How do I buy shares of Xeris Biopharma?

Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XERS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners